Understand the source comparison
Peptide News July 2026: Compound Comparison
Peptide news July 2026 introduced multiple compounds with overlapping but distinct mechanisms. Understanding which molecule fits specific research applications requires comparing receptor targets, half-life profiles, and documented efficacy endpoints. Survodut
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptide news July 2026 introduced multiple compounds with overlapping but distinct mechanisms. Understanding which molecule fits specific research applications requires comparing receptor targets, half-life profiles, and documented efficacy endpoints.
- Survodutide
- GLP-1/GIP/glucagon triple agonist
- ~7 days
- 18.6% weight reduction at 68 weeks (SYNCHRONIZE-2); 74% achieved ≥30% liver fat reduction
- Obesity, NAFLD/NASH, metabolic syndrome models
- Most effective metabolic peptide in late-stage trials; glucagon component differentiates it from dual agonists
- Retatrutide
- ~6 days
- 24.2% weight reduction at 48 weeks (Phase II TRIUMPH-1); Phase III ongoing
- Obesity, body composition studies, appetite regulation pathways
- Highest weight-loss efficacy to date; shorter trial duration limits long-term data vs survodutide
- Tirzepatide
- GLP-1/GIP dual agonist
- ~5 days
- 14.9% weight reduction at 68 weeks (SURMOUNT-1); removed from FDA shortage list July 9, 2026
- Type 2 diabetes, obesity, incretin receptor signaling
- No longer compoundable after Sept 7; legacy standard but eclipsed by triple agonists
- Mazdutide
- GLP-1/glucagon dual agonist
- ~8 days
- Phase II data: 12.4% weight reduction at 24 weeks; improved hepatic insulin sensitivity
- Metabolic research, glucagon receptor studies, hepatic glucose regulation
- Investigational status allows continued 503B compounding; useful for isolating glucagon effects
- FOXO4-DRI
- FOXO4-p53 interaction inhibitor (senolytic)
- ~4 hours (IV)
- Phase I complete: dose-dependent senescent cell reduction; Phase IIa IPF trial initiated July 2026
- Senescence, fibrosis, aging intervention, SASP modulation
- First peptide senolytic in human efficacy trials; represents new therapeutic class beyond metabolism